Estrogen receptor corepressors - A role in human breast cancer?

Endocrine-Related Cancer

Volumn 10, Issue 4, 2003, Pages 517-536

  Dobrzycka, K M ^a   Townson, S M ^a   Jiang, S ^a   Oesterreich, Steffi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR; COREPRESSOR PROTEIN; DEAD BOX PROTEIN; DSS AHC CRITICAL REGION ON THE X GENE 1; ESTROGEN RECEPTOR; FORKHEAD HOMOLOG IN RHABDOMYOSARCOMA; HISTONE; METASTASIS ASSOCIATED PROTEIN 1; NEDD8 PROTEIN; NUCLEAR RECEPTOR BINDING SET DOMAIN CONTAINING PROTEIN 1; NUCLEAR RECEPTOR COREPRESSOR; POLYPYRIMIDINE TRACT BINDING PROTEIN; RECEPTOR INTERACTING PROTEIN 140; REPRESSOR OF ESTROGEN RECEPTOR ALPHA ACTIVITY; REPRESSOR OF TAMOXIFEN TRANSCRIPTIONAL ACTIVITY; REPRESSOR PROTEIN; SCAFFOLD ATTACHMENT FACTOR B1; SHORT HETERODIMER PARTNER; SILENCING MEDIATOR OF RETINOIC ACID RECEPTOR AND THYROID HORMONE RECEPTOR; SMALL UNIQUE NUCLEAR RECEPTOR COREPRESSOR; SMRT HDAC1 ASSOCIATED REPRESSOR PROTEIN; STEROID RECEPTOR; TESTICULAR RECEPTOR 2; TRUNCATED ESTROGEN RECEPTOR PRODUCT 1; UNCLASSIFIED DRUG;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER RESISTANCE; CHROMATIN STRUCTURE; DEACETYLATION; DIMERIZATION; DNA BINDING; DNA REPAIR; GENE CONTROL; HORMONAL THERAPY; HORMONE RESPONSE; HUMAN; NONHUMAN; PROTEIN STABILITY; REVIEW; RNA PROCESSING; SIGNAL TRANSDUCTION; TISSUE CULTURE; TRANSCRIPTION INITIATION;

BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC;

EID: 0345826225     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0100517     Document Type: Review

References (192)

1. Alland L, Muhle R, Hou H Jr, Potes J, Chin L, Schreiber-Agus N & DePinho RA 1997 Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 387 49-55.
2. Auboeuf D, Honig A, Berget SM & O'Malley BW 2002 Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science 298 416-419.
3. Balasenthil S & Vadlamudi RK 2003 Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. Journal of Biological Chemistry 278 22119-22127.
4. Baniahmad A, Kohne AC & Renkawitz R 1992 A transferable silencing domain is present in the thyroid hormone receptor, in the v-erbA oncogene product and in the retinoic acid receptor. EMBO Journal 11 1015-1023.
5. Bautista S, Valles H, Walker RL, Anzick S, Zeillinger R, Meltzer P & Theillet C 1998 In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clinical Cancer Research 4 2925-2929.
6. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM & Osborne CK 1992 Estrogen-dependant, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Research and Treatment 24 85-95.
7. Brodie SG & Deng CX 2001 BRCA1-associated tumorigenesis: what have we learned from knockout mice? Trends in Genetics 17 S18-S22.
8. Brown M & Sharp PA 1990 Human estrogen receptor forms multiple protein-DNA complexes. Journal of Biological Chemistry 265 11238-11243.
9. Brzovic PS, Keeffe JR, Nishikawa H, Miyamoto K, Fox D 3rd, Fukuda M, Ohta T & Klevit R 2003 Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex. PNAS 100 5646-5651.
10. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA & Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 753-758.
11. Budhram-Mahadeo V, Parker M & Latchman DS 1998 POU transcription factors Brn-3a and Brn-3b interact with the estrogen receptor and differentially regulate transcriptional activity via an estrogen response element. Molecular and Cellular Biology 18 1029-1041.
12. Cavailles V, Dauvois S, L'Horset F, Lopez G, Hoare S, Kushner PJ & Parker MG 1995 Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO Journal 14 3741-3751.
13. Cavalieri EL & Rogan EG 2002 A unified mechanism in the initiation of cancer. Annals of the New York Academy of Sciences 959 341-354.
14. Chan CM, Lykkesfeldt AE, Parker MG & Dowsett M 1999 Expression of nuclear receptor interacting proteins TIF-1, SUG-1, receptor interacting protein 140, and corepressor SMRT in tamoxifen-resistant breast cancer. Clinical Cancer Research 5 3460-3467.
15. Charpentier AH, Bednarek AK, Daniel RL, Hawkins KA, Laflin KJ, Gaddis S, MacLeod MC & Aldaz CM 2000 Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Research 60 5977-5983.
16. Chen JD & Evans RM 1995 A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377 454-457.
17. Chinnadurai G 2002 CtBP, an unconventional transcriptional corepressor in development and oncogenesis. Molecular Cell 9 213-224.
18. Chong MT & Lippman ME 1982 Effects of RNA and ribonuclease on the binding of estrogen and glucocorticoid receptors from MCF-7 cells to DNA-cellulose. Journal of Biological Chemistry 257 2996-3002.
19. Cid MC, Schnaper HW & Kleinman HK 2002 Estrogens and the vascular endothelium. Annals of the New York Academy of Sciences 966 143-157.
20. Deckert J & Struhl K 2001 Histone acetylation at promoters is differentially affected by specific activators and repressors. Molecular and Cellular Biology 21 2726-2735.
21. Delage-Mourroux R, Martini PG, Choi I, Kraichely DM, Hoeksema J & Katzenellenbogen BS 2000 Analysis of estrogen receptor interaction with a repressor of estrogen receptor activity (REA) and the regulation of estrogen receptor transcriptional activity by REA. Journal of Biological Chemistry 275 35848-35856.
22. Deng CX 2002 Tumor formation in Brca1 conditional mutant mice. Environmental and Molecular Mutagenesis 39 171-177.
23. Deng CX & Brodie SG 2001 Knockout mouse models and mammary tumorigenesis. Seminars in Cancer Biology 11 387-394.
24. Dhandapani KM & Brann DW 2002 Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biology of Reproduction 67 1379-1385.
25. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS & Bradley A 1992 Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356 215-221.
26. Dressel U, Thormeyer D, Altincicek B, Paululat A, Eggert M, Schneider S, Tenbaum SP, Renkawitz R & Baniahmad A 1999 Alien, a highly conserved protein with characteristics of a corepressor for members of the nuclear hormone receptor superfamily. Molecular and Cellular Biology 19 3383-3394.
27. Escriva H, Delaunay F & Laudet V 2000 Ligand binding and nuclear receptor evolution. BioEssays 22 717-727.
28. Fan M, Bigsby RM & Nephew KP 1999 BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284 1354-1356.
29. Fan M, Long X, Bailey JA, Reed CA, Osborne E, Gize EA, Kirk EA, Bigsby RM & Nephew KP 2001 Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 20 77-87.
30. Fan S, Ma YX, Wang C, Yuan RQ, Meng Q, Wang JA, Erdos M, Goldberg ID, Webb P, Kushner PJ et al. 2002 The activating enzyme of NEDD8 inhibits steroid receptor function. Molecular Endocrinology 16 315-330.
31. Fan M, Bigsby RM & Nephew KP 2003 The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells. Molecular Endocrinology 17 356-365.
32. Fernandes I, Bastien Y, Wai T, Nygard K, Lin R, Cormier O, Lee HS, Eng F, Bertos NR, Pelletier N et al. 2003 Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. Molecular Cell 11 139-150.
33. Franco PJ, Farooqui M, Seto E & Wei LN 2001 The orphan nuclear receptor TR2 interacts directly with both class I and class II histone deacetylases. Molecular Endocrinology 15 1318-1328.
34. Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS & Wade PA 2003 MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 113 207-219.
35. Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R & Bieche I 2003 Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clinical Cancer Research 9 1259-1266.
36. Glass CK, Rose DW & Rosenfeld MG 1997 Nuclear receptor coactivators. Current Opinion in Cell Biology 2 222-232.
37. Gottardis MM, Saceda M, Garcia-Morales P, Fung YK, Solomon H, Sholler PF, Lippman ME & Martin MB 1995 Regulation of retinoblastoma gene expression in hormone-dependent breast cancer. Endocrinology 136 5659-5665.
38. Guenther MG, Lane WS, Fischle W, Verdin E, Lazar MA & Shiekhattar R 2000 A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes and Development 14 1048-1057.
39. Hall JM & McDonnell DP 1999 The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140 5566-5578.
40. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B & King MC 1990 Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250 1684-1689.
41. Hall JM, McDonnell DP & Korach KS 2002 Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. Molecular Endocrinology 16 469-486.
42. Heery DM, Hoare S, Hussain S, Parker MG & Sheppard H 2001 Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors. Journal of Biological Chemistry 276 6695-6702.
43. Heinzel T, Lavinsky RM, Mullen TM, Soderstrom M, Laherty CD, Torchia J, Yang WM, Brard G, Ngo SD, Davie JR et al. 1997 A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387 43-48.
44. Hermanson O, Glass CK & Rosenfeld MG 2002 Nuclear receptor coregulators: multiple modes of modification. Trends in Endocrinology and Metabolism 13 55-60.
45. Hodges LC, Cook JD, Lobenhofer EK, Li L, Bennett L, Bushel PR, Aldaz CM, Afshari CA & Walker CL 2003 Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Molecular Cancer Research 1 300-311.
46. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Soderstrom M, Glass CK et al. 1995 Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377 397-404.
47. Hu X & Lazar MA 1999 The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402 93-96.
48. Hu X, Li Y & Lazar MA 2001 Determinants of CoRNR-dependent repression complex assembly on nuclear hormone receptors. Molecular and Cellular Biology 21 1747-1758.
49. Hu YC, Shyr CR, Che W, Mu XM, Kim E & Chang C 2002 Suppression of estrogen receptor-mediated transcription and cell growth by interaction with TR2 orphan receptor. Journal of Biological Chemistry 277 33571-33579.
50. Huang EY, Zhang J, Miska EA, Guenther MG, Kouzarides T & Lazar MA 2000 Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes and Development 14 45-54.
51. Huang HJ, Norris JD & McDonnell DP 2002 Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. Molecular Endocrinology 16 1778-1792.
52. Huang N, vom Baur E, Garnier JM, Lerouge T, Vonesch JL, Lutz Y, Chambon P & Losson R 1998 Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators. EMBO Journal 17 3398-3412.
53. Inoue S, Orimo A, Hosoi T, Kondo S, Toyoshima H, Kondo T, Ikegami A, Ouchi Y, Orimo H & Muramatsu M 1993 Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. PNAS 90 11117-11121.
54. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L & Horwitz KB 1997 The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Molecular Endocrinology 11 693-705.
55. Jakacka M, Ito M, Weiss J, Chien PY, Gehm BD & Jameson JL 2001 Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. Journal of Biological Chemistry 276 13615-13621.
56. Jepsen K & Rosenfeld MG 2002 Biological roles and mechanistic actions of co-repressor complexes. Journal of Cell Science 115 689-698.
57. Jepsen K, Hermanson O, Onami TM, Gleiberman AS, Lunyak V, McEvilly RJ, Kurokawa R, Kumar V, Liu F, Seto E et al. 2000 Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102 753-763.
58. Johansson L, Thomsen JS, Damdimopoulos AE, Spyrou G, Gustafsson JA & Treuter E 1999 The orphan nuclear receptor SHP inhibits agonist-dependent transcriptional activity of estrogen receptor alpha and beta. Journal of Biological Chemistry 274 345-353.
59. Johansson L, Bavner A, Thomsen JS, Farnegardh M, Gustafsson JA & Treuter E 2000 The orphan nuclear receptor SHP utilizes conserved LXXLL-related motifs for interactions with ligand-activated estrogen receptors. Molecular and Cellular Biology 20 1124-1133.
60. Kao HY, Downes M, Ordentlich P & Evans RM 2000 Isolation of a novel histone deacetylase reveals that class I and class II deacetylases promote SMRT-mediated repression. Genes and Development 14 55-66.
61. Kato S, Kitamoto T, Masuhiro Y & Yanagisawa J 1998 Molecular mechanism of a cross-talk between estrogen and growth-factor signaling pathways. Oncology 55 5-10.
62. Keen JC & Davidson NE 2003 The biology of breast carcinoma. Cancer 97 825-833.
63. Kelley KM, Rowan BG & Ratnam M 2003 Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting. Cancer Research 63 2820-2828.
64. Kim J, Petz LN, Ziegler YS, Wood JR, Potthoff SJ & Nardulli AM 2000 Regulation of the estrogen-responsive pS2 gene in MCF-7 human breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 74 157-168.
65. Klinge CM 2000 Estrogen receptor interaction with co-activators and co-repressors. Steroids 65 227-251.
66. Klinge CM 2001 Estrogen receptor interaction with estrogen response elements. Nucleic Acids Research 29 2905-2919.
67. Klinge CM, Silver BF, Driscoll MD, Sathya G, Bambara RA & Hilf R 1997 Chicken ovalbumin upstream promoter-transcription factor interacts with estrogen receptor, binds to estrogen response elements and half-sites, and inhibits estrogen-induced gene expression. Journal of Biological Chemistry 272 31465-31474.
68. Klinge CM, Jernigan SC & Risinger KE 2002 The agonist activity of tamoxifen is inhibited by the short heterodimer partner orphan nuclear receptor in human endometrial cancer cells. Endocrinology 143 853-867.
69. Kokura K, Kaul SC, Wadhwa R, Nomura T, Khan MM, Shinagawa T, Yasukawa T, Colmenares C & Ishii S 2001 The Ski protein family is required for MeCP2-mediated transcriptional repression. Journal of Biological Chemistry 276 34115-34121.
70. Kraus RJ, Ariazi EA, Farrell ML & Mertz JE 2002 Estrogen-related receptor alpha 1 actively antagonizes estrogen receptor-regulated transcription in MCF-7 mammary cells. Journal of Biological Chemistry 277 24826-24834.
71. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S & Gustafsson JA 1996 Cloning of a novel receptor expressed in rat prostate and ovary. PNAS 93 5925-5930.
72. Kumar R, Wang RA, Mazumdar A, Talukder AH, Mandal M, Yang Z, Bagheri-Yarmand R, Sahin A, Hortobagyi G, Adam L et al. 2002 A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature 418 654-657.
73. Kurebayashi J, Otsuki T, Kunisue H, Tanaka K, Yamamoto S & Sonoo H 2000 Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clinical Cancer Research 6 512-518.
74. Kurokawa H, Lenferink A, Simpson J, Pisacane P, Sliwkowski M, Forbes J & Arteaga C 2000 Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Research 60 5887-5894.
75. Kurokawa R, Soderstrom M, Horlein A, Halachmi S, Brown M, Rosenfeld MG & Glass CK 1995 Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature 377 451-454.
76. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM & Webb P 2000 Estrogen receptor pathways to AP-1. Journal of Steroid Biochemistry and Molecular Biology 74 311-317.
77. Lanz RB, McKenna NJ, Onate SA, Albrecht U, Wong J, Tsai SY, Tsai MJ & O'Malley BW 1999 A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 97 17-27.
78. Lauritsen KJ, List HJ, Reiter R, Wellstein A & Riegel AT 2002 A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells. Oncogene 21 7147-7155.
79. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J et al. 1998 Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. PNAS 95 2920-2925.
80. Lee CH & Wei LN 1999 Characterization of receptor-interacting protein 140 in retinoid receptor activities. Journal of Biological Chemistry 274 31320-31326.
81. Lee CH, Chinpaisal C & Wei LN 1998 Cloning and characterization of mouse RIP140, a corepressor for nuclear orphan receptor TR2. Molecular and Cellular Biology 18 6745-6755.
82. Levin ER 2002 Cellular functions of plasma membrane estrogen receptors. Steroids 67 471-475.
83. Levine AJ 1997 p53, the cellular gatekeeper for growth and division. Cell 88 323-331.
84. Li J, Wang J, Nawaz Z, Liu JM, Qin J & Wong J 2000 Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO Journal 19 4342-4350.
85. Li J, Lin Q, Wang W, Wade P & Wong J 2002a Specific targeting and constitutive association of histone deacetylase complexes during transcriptional repression. Genes and Development 16 687-692.
86. Li X, Kimbrel EA, Kenan DJ & McDonnell DP 2002b Direct interactions between corepressors and coactivators permit the integration of nuclear receptor-mediated repression and activation. Molecular Endocrinology 16 1482-1491.
87. Likhite VS, Kass EI, Nardulli AM, Anderson SD & Yates JR 2003 A novel interaction between estrogen receptor and 3-methyladenine DNA glycosylase. The Endocrine Society's 85th Annual Meeting, Philadelphia, PA, USA.
88. Liu G, Schwartz JA & Brooks SC 1999 p53 down-regulates ER-responsive genes by interfering with the binding of ER to ERE. Biochemical and Biophysical Research Communications 264 359-364.
89. Liu Y, Asch H & Kulesz-Martin MF 2001 Functional quantification of DNA-binding proteins p53 and estrogen receptor in cells and tumor tissues by DNA affinity immunoblotting. Cancer Research 61 5402-5406.
90. Loven MA, Muster N, Yates JR & Nardulli AM 2003a A novel ER-associated protein represses ER-mediated transcription and alters ER-DNA interactions. The Endocrine Society's 85th Annual Meeting, Philadelphia, PA, USA.
91. Loven MA, Muster N, Yates JR & Nardulli AM 2003b A novel estrogen receptor alpha-associated protein, template-activating factor I beta, inhibits acetylation and transactivation. Molecular Endocrinology 17 67-78.
92. McDonnell DP & Norris JD 2002 Connections and regulation of the human estrogen receptor. Science 296 1642-1644.
93. McKenna NJ & O'Malley BW 2002 Minireview: nuclear receptor coactivators - an update. Endocrinology 143 2461-2465.
94. McKenna NJ, Lanz RB & O'Malley BW 1999 Nuclear receptor coregulators: cellular and molecular biology. Endocrine Reviews 20 321-344.
95. Martens JH, Verlaan M, Kalkhoven E, Dorsman JC & Zantema A 2002 Scaffold/matrix attachment region elements interact with a p300-scaffold attachment factor A complex and are bound by acetylated nucleosomes. Molecular and Cellular Biology 22 2598-2606.
96. Martin MD, Fischbach K, Osborne CK, Mohsin SK, Allred DC & O'Connell P 2001 Loss of heterozygosity events impeding breast cancer metastasis contain the MTA1 gene. Cancer Research 61 3578-3580.
97. Mathur M, Tucker PW & Samuels HH 2001 PSF is a novel corepressor that mediates its effect through Sin3A and the DNA binding domain of nuclear hormone receptors. Molecular and Cellular Biology 21 2298-2311.
98. Mazumdar A, Wang RA, Mishra SK, Adam L, Bagheri-Yarmand R, Mandal M, Vadlamudi RK & Kumar R 2001 Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nature Cell Biology 3 30-37.
99. Mendelsohn ME 2002a Genomic and nongenomic effects of estrogen in the vasculature. American Journal of Cardiology 90 3F-6F.
100. Mendelsohn ME 2002b Protective effects of estrogen on the cardiovascular system. American Journal of Cardiology 89 12E-17E; discussion 17E-18E.
101. Miki Y, Swensen J, Shattuck-Eidens D et al. 1994 A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 66-71.
102. Monsalve M, Wu Z, Adelmant G, Puigserver P, Fan M & Spiegelman BM 2000 Direct coupling of transcription and mRNA processing through the thermogenic coactivator PGC-1. Molecular Cell 6 307-316.
103. Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P & Katzenellenbogen BS 1999 An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. PNAS 96 6947-6952.
104. Monteiro AN 2000 BRCA1: exploring the links to transcription. Trends in Biochemical Sciences 25 469-474.
105. Moore DD 1990 Diversity and unity in the nuclear hormone receptors: a terpenoid receptor superfamily. New Biology 2 100-105.
106. Morrison AJ, Herrera RE, Heinsohn EC, Schiff R & Osborne CK 2003 Dominant negative N-CoR relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. Molecular Endocrinology 17 1534-1554.
107. Moynahan ME 2002 The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans. Oncogene 21 8994-9007.
108. Murphy LC, Simon SL, Parkes A, Leygue E, Dotzlaw H, Snell L, Troup S, Adeyinka A & Watson PH 2000 Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Research 60 6266-6271.
109. Murphy LC, Leygue E, Niu Y, Snell L, Ho SM & Watson PH 2002 Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. British Journal of Cancer 87 1411-1416.
110. Muscat GE, Burke LJ & Downes M 1998 The corepressor N-CoR and its variants RIP13a and RIP13Delta1 directly interact with the basal transcription factors TFIIB, TAFII32 and TAFII70. Nucleic Acids Research 26 2899-2907.
111. Nagy L, Kao H-Y, Chakravarti D, Lin R, Hassig C, Ayer D, Schreiber S & Evans R 1997 Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 69 373-380.
112. Nawaz Z, Lonard DM, Dennis AP, Smith CL & O'Malley BW 1999 Proteasome-dependent degradation of the human estrogen receptor. PNAS 96 1858-1862.
113. Nayler O, Stratling W, Bourquin JP, Stagljar I, Lindemann L, Jasper H, Hartmann AM, Fackelmayer FO, Ullrich A & Stamm S 1998 SAF-B protein couples transcription and pre-mRNA splicing to SAR/MAR elements. Nucleic Acids Research 26 3542-3549.
114. Newman SP, Bates NP, Vernimmen D, Parker MG & Hurst HC 2000 Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 19 490-497.
115. Nicolson GL, Nawa A, Toh Y, Taniguchi S, Nishimori K & Moustafa A 2003 Tumor metastasis-associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation. Clinical and Experimental Metastasis 20 19-24.
116. Norris JD, Fan D, Sherk A & McDonnell DP 2002 A negative coregulator for the human ER. Molecular Endocrinology 16 459-468.
117. Nye AC, Rajendran RR, Stenoien DL, Mancini MA, Katzenellenbogen BS & Belmont AS 2002 Alteration of large-scale chromatin structure by estrogen receptor. Molecular and Cellular Biology 22 3437-3449.
118. Oesterreich S, Lee AV, Sullivan TM, Samuel SK, Davie JR & Fuqua SA 1997 Novel nuclear matrix protein HET binds to and influences activity of the HSP27 promoter in human breast cancer cells. Journal of Cellular Biochemistry 67 275-286.
119. Oesterreich S, Zhang Q, Hopp T, Fuqua SA, Michaelis M, Zhao HH, Davie JR, Osborne CK & Lee AV 2000 Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Molecular Endocrinology 14 369-381.
120. Oesterreich S, Allredl DC, Mohsin SK, Zhang Q, Wong H, Lee AV, Osborne CK & O'Connell P 2001 High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer. British Journal of Cancer 84 493-498.
121. Oesterreich S, Kang K, Townson S, Clark GM, Hilsenbeck SG, Osborne C & Bardou V 2002 Critical balance of scaffold attachment factor SAFB levels plays important role in breast tumor suppression. 25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA.
122. Oesterreich S, Deng W, Jiang S, Cui X, Ivanova M, Schiff R, Kang K, Hadsell D, Behrens J & Lee AV 2003 Estrogen-mediated downregulation of E-cadherin in breast cancer cells. Cancer Research 63 5203-5208.
123. Ordentlich P, Downes M, Xie W, Genin A, Spinner NB & Evans RM 1999 Unique forms of human and mouse nuclear receptor corepressor SMRT. PNAS 96 2639-2644.
124. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL & Nicholson RI 1995 Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. Journal of the National Cancer Institute 87 746-750.
125. Osborne CK, Schiff R, Fuqua SA & Shou J 2001 Estrogen receptor: current understanding of its activation and modulation. Clinical Cancer Research 7 4338s-4342s, discussion 4411s-4412s.
126. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM & Schiff R 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. Journal of the National Cancer Institute 95 353-361.
127. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ & Scanlan TS 1997 Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277 1508-1510.
128. Palmieri C, Cheng GJ, Saji S, Zelada-Hedman M, Warri A, Weihua Z, Van Noorden S, Wahlstrom T, Coombes RC, Warner M et al. 2002 Estrogen receptor beta in breast cancer. Endocrine Related Cancer 9 1-13.
129. Parker M, Leonardsson G, White R, Steel J & Milligan S 2003 Identification of RIP140 as a nuclear receptor cofactor with a role in female reproduction. FEBS Letters 546 149-153.
130. Pereira FA, Qiu Y, Zhou G, Tsai MJ & Tsai SY 1999 The orphan nuclear receptor COUP-TFII is required for angiogenesis and heart development. Genes and Development 13 1037-1049.
131. Perissi V, Staszewski LM, McInerney EM, Kurokawa R, Krones A, Rose DW, Lambert MH, Milburn MV, Glass CK & Rosenfeld MG 1999 Molecular determinants of nuclear receptor-corepressor interaction. Genes and Development 13 3198-3208.
132. Polly P, Herdick M, Moehren U, Baniahmad A, Heinzel T & Carlberg C 2000 VDR-Alien: a novel, DNA-selective vitamin D(3) receptor-corepressor partnership. FASEB Journal 14 1455-1463.
133. Powles TJ 2002 Anti-oestrogenic prevention of breast cancer-the make or break point. Nature Reviews Cancer 2 787-794.
134. Qiu Y, Pereira FA, DeMayo FJ, Lydon JP, Tsai SY & Tsai MJ 1997 Null mutation of mCOUP-TFI results in defects in morphogenesis of the glossopharyngeal ganglion, axonal projection, and arborization. Genes and Development 11 1925-1937.
135. Rajendran RR, Nye AC, Frasor J, Balsara RD, Martini PG & Katzenellenbogen BS 2003 Regulation of nuclear receptor transcriptional activity by a novel DEAD box RNA helicase (DP97). Journal of Biological Chemistry 278 4628-4638.
136. Rayasam GV, Wendling O, Angrand PO, Mark M, Niederreither K, Song L, Lerouge T, Hager GL, Chambon P & Losson R 2003 NSD1 is essential for early post-implantation development and has a catalytically active SET domain. EMBO Journal 22 3153-3163.
137. Read LD, Keith D Jr, Slamon DJ & Katzenellenbogen BS 1990 Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Research 50 3947-3951.
138. Reese JC & Katzenellenbogen BS 1992 Examination of the DNA-binding ability of estrogen receptor in whole cells: implications for hormone-independent transactivation and the actions of antiestrogens. Molecular and Cellular Biology 12 4531-4538.
139. Reid G, Hubner MR, Metivier R, Brand H, Denger S, Manu D, Beaudouin J, Ellenberg J & Gannon F 2003 Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Molecular Cell 11 695-707.
140. Renz A & Fackelmayer FO 1996 Purification and molecular cloning of the scaffold attachment factor B (SAF-B), a novel human nuclear protein that specifically binds to S/MAR-DNA. Nucleic Acids Research 24 843-849.
141. Resnick EM, Schreihofer DA, Periasamy A & Shupnik MA 2000 Truncated estrogen receptor product-1 suppresses estrogen receptor transactivation by dimerization with estrogen receptors alpha and beta. Journal of Biological Chemistry 275 7158-7166.
142. Safe S 2001 Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitamins and Hormones 62 231-252.
143. Santen RJ 2002 To block estrogen's synthesis or action: that is the question. Journal of Clinical Endocrinology and Metabolism 87 3007-3012.
144. Schiff R, Massarweh S, Shou J & Osborne CK 2003 Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clinical Cancer Research 9 447S-454S.
145. Schulman IG, Juguilon H & Evans RM 1996 Activation and repression by nuclear hormone receptors: hormone modulates an equilibrium between active and repressive states. Molecular and Cellular Biology 16 3807-3813.
146. Schuur ER, Loktev AV, Sharma M, Sun Z, Roth RA & Weigel RJ 2001 Ligand-dependent interaction of estrogen receptor-alpha with members of the forkhead transcription factor family. Journal of Biological Chemistry 276 33554-33560.
147. Seol W, Choi HS & Moore DD 1996 An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors. Science 272 1336-1339.
148. Seol W, Hanstein B, Brown M & Moore DD 1998 Inhibition of estrogen receptor action by the orphan receptor SHP (short heterodimer partner). Molecular Endocrinology 12 1551-1557.
149. Shang Y & Brown M 2002 Molecular determinants for the tissue specificity of SERMs. Science 295 2465-2468.
150. Shang Y, Hu X, DiRenzo J, Lazar MA & Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103 843-852.
151. Shi H & Xu RM 2003 Crystal structure of the Drosophila Mago nashi-Y14 complex. Genes and Development 17 971-976.
152. Shi Y, Downes M, Xie W, Kao HY, Ordentlich P, Tsai CC, Hon M & Evans RM 2001 Sharp, an inducible cofactor that integrates nuclear receptor repression and activation. Genes and Development 15 1140-1151.
153. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA & Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 927-937.
154. Simon SL, Parkes A, Leygue E, Dotzlaw H, Snell L, Troup S, Adeyinka A, Watson PH & Murphy LC 2000 Expression of a repressor of estrogen receptor activity in human breast tumors: relationship to some known prognostic markers. Cancer Research 60 2796-2799.
155. Smith CL, Nawaz Z & O'Malley BW 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Molecular Endocrinology 11 657-666.
156. Somasundaram K 2003 Breast cancer gene 1 (BRCA1): role in cell cycle regulation and DNA repair - perhaps through transcription. Journal of Cellular Biochemistry 88 1084-1091.
157. Stoner M, Wang F, Wormke M, Nguyen T, Samudio I, Vyhlidal C, Marme D, Finkenzeller G & Safe S 2000 Inhibition of vascular endothelial growth
158. Teo AK, Oh HK, Ali RB & Li BF 2001 The modified human DNA repair enzyme O(6)-methylguanine-DNA methyl transferase is a negative regulator of estrogen receptor mediated transcription upon alkylation DNA damage. Molecular and Cellular Biology 21 7105-7114.
159. Teyssier C, Belguise K, Galtier F, Cavailles V & Chalbos D 2003 Receptor-interacting protein 140 binds c-jun and inhibits estradiol-induced activator protein-1 activity by reversing glucocorticoid receptor-interacting protein 1 effect. Molecular Endocrinology 17 287-299.
160. Thenot S, Charpin M, Bonnet S & Cavailles V 1999 Estrogen receptor cofactors expression in breast and endometrial human cancer cells. Molecular and Cellular Endocrinology 156 85-93.
161. Toh Y, Pencil SD & Nicolson GL 1994 A novel candidate metastasis-associated gene, mta1, differentially expressed in highly metastatic mammary adenocarcinoma cell lines. cDNA cloning, expression, and protein analyses. Journal of Biological Chemistry 269 22958-22963.
162. Townson SM, Sullivan T, Zhang Q, Clark GM, Osborne CK, Lee AV & Oesterreich S 2000 HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer. Clinical Cancer Research 6 3788-3796.
163. Townson SM, Dobrzycka KM, Lee AV, Air M, Deng W, Kang K, Jiang S, Kioka N, Michaelis K & Oesterreich S 2003 SAFB2, a new scaffold attachment factor homolog and estrogen receptor corepressor. Journal of Biological Chemistry 278 20059-20068.
164. Tremblay GB & Giguere V 2002 Coregulators of estrogen receptor action. Critical Reviews in Eukaryotic Gene Expression 12 1-22.
165. Treuter E, Albrektsen T, Johansson L, Leers J & Gustafsson J-A 1998 A regulatory role for RIP140 in nuclear receptor activation. Molecular Endocrinology 12 864-881.
166. Ueki N & Hayman MJ 2003 Signal-dependent N-CoR requirement for repression by the Ski oncoprotein. Journal of Biological Chemistry 278 24858-24864.
167. Valverde MA & Parker MG 2002 Classical and novel steroid actions: a unified but complex view. Trends in Biochemical Sciences 27 172-173.
168. Vanacker JM, Bonnelye E, Delmarre C & Laudet V 1998 Activation of the thyroid hormone receptor alpha gene promoter by the orphan nuclear receptor ERR alpha. Oncogene 17 2429-2435.
169. Vanacker JM, Bonnelye E, Chopin-Delannoy S, Delmarre C, Cavailles V & Laudet V 1999 Transcriptional activities of the orphan nuclear receptor ERR alpha (estrogen receptor-related receptor-alpha). Molecular Endocrinology 13 764-773.
170. Venkitaraman AR 2002 Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108 171-182.
171. Wahl GM & Carr AM 2001 The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nature Cell Biology 3 E277-286.
172. Watanabe H, Suzuki A, Mizutani T, Khono S, Lubahn DB, Handa H & Iguchi T 2002 Genome-wide analysis of changes in early gene expression induced by oestrogen. Genes Cells 7 497-507.
173. Watanabe T, Inoue S, Hiroi H, Orimo A, Kawashima H & Muramatsu M 1998 Isolation of estrogen-responsive genes with a CpG island library. Molecular and Cellular Biology 18 442-449.
174. Wei LN, Hu X, Chandra D, Seto E & Farooqui M 2000 Receptor-interacting protein 140 directly recruits histone deacetylases for gene silencing. Journal of Biological Chemistry 275 40782-40787.
175. Weighardt F, Cobianchi F, Cartegni L, Chiodi I, Villa A, Riva S & Biamonti G 1999 A novel hnRNP protein (HAP/SAF-B) enters a subset of hnRNP complexes and relocates in nuclear granules in response to heat shock. Journal of Cell Science 112 1465-1476.
176. Weihua Z, Saji S, Makinen S, Cheng G, Jensen EV, Warner M & Gustafsson JA 2000 Estrogen receptor (ER) beta, a modulator of ER alpha in the uterus. PNAS 97 5936-5941.
177. White R, Leonardsson G, Rosewell I, Ann Jacobs M, Milligan S & Parker M 2000 The nuclear receptor co-repressor nripl (RIP140) is essential for female fertility. Nature Medicine 6 1368-1374.
178. Wong AK, Ormonde PA, Pero R, Chen Y, Lian L, Salada G, Berry S, Lawrence Q, Dayananth P, Ha P et al. 1998 Characterization of a carboxy-terminal BRCA1 interacting protein. Oncogene 17 2279-2285.
179. Wong CW, McNally C, Nickbarg E, Komm BS & Cheskis BJ 2002 Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. PNAS 99 14783-14788.
180. Wu L, Wu Y, Gathings B, Wan M, Li X, Grizzle W, Liu Z, Lu C, Mao Z & Cao X 2003 Smad4 as a transcription corepressor for estrogen receptor alpha. Journal of Biological Chemistry 278 15192-15200.
181. Xu HE, Stanley TB, Montana VG, Lambert MH, Shearer BG, Cobb JE, McKee DD, Galardi CM, Plunket KD, Nolte RT et al. 2002 Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 415 813-817.
182. Xu J, Nawaz Z, Tsai SY, Tsai MJ & O'Malley BW 1996 The extreme C terminus of progesterone receptor contains a transcriptional repressor domain that functions through a putative corepressor. PNAS 93 12195-12199.
183. Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A & Deng CX 1999 Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nature Genetics 22 37-43.
184. Yang A, Kaghad M, Caput D & McKeon F 2002 On the shoulders of giants: p63, p73 and the rise of p53. Trends in Genetics 18 90-95.
185. Yu CL, Driggers P, Barrera-Hernandez G, Nunez SB, Segars JH & Cheng S 1997 The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. Biochemical and Biophysical Research Communications 239 617-620.
186. Yu RN, Ito M, Saunders TL, Camper SA & Jameson JL 1998a Role of Ahch in gonadal development and gametogenesis. Nature Genetics 20 353-357.
187. Yu X, Wu LC, Bowcock AM, Aronheim A & Baer R 1998b The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. Journal of Biological Chemistry 273 25388-25392.
188. Zamir I, Dawson J, Lavinsky RM, Glass CK, Rosenfeld MG & Lazar MA 1997 Cloning and characterization of a corepressor and potential component of the nuclear hormone receptor repression complex. PNAS 94 14400-14405.
189. Zhang H, Thomsen JS, Johansson L, Gustafsson JA & Treuter E 2000 DAX-1 functions as an LXXLL-containing corepressor for activated estrogen receptors. Journal of Biological Chemistry 275 39855-39859.
190. Zhang X, Jeyakumar M, Petukhov S & Bagchi MK 1998 A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Molecular Endocrinology 12 513-524.
191. Zhao HH, Herrera RE, Coronado-Heinsohn E, Yang MC, Ludes-Meyers JH, Seybold-Tilson KJ, Nawaz Z, Yee D, Barr FG, Diab SG et al. 2001 Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. Journal of Biological Chemistry 276 27907-27912.
192. Zheng L, Annab LA, Afshari CA, Lee WH & Boyer TG 2001 BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. PNAS 98 9587-9592.